The pharmacodynamic effects of oral anticoagulants (OACs) on the coagulation pathway
and the effect of antiplatelet therapy (APT) on platelet activation, used in isolation, have …

In patients requiring dual antiplatelet therapy (DAPT) who also have an indication to be
treated with oral anticoagulant (OAC) drugs, aspirin withdrawal reduces the risk of bleeding …

Background: The impact of non-vitamin K antagonist oral anticoagulants (NOACs) on
platelet function is still unclear. We conducted a comprehensive ex vivo study aimed at …

Nonvitamin K oral anticoagulants (NOACs) or direct oral anticoagulants comprise inhibitors
of factor Xa (rivaroxaban, apixaban, edoxaban) or factor IIa (dabigatran). Both classes …

Non-vitamin K antagonist oral anticoagulants (NOACs) reduce the risk of thromboembolism
in patients with atrial fibrillation (AF). There has been no head-to-head comparison of the …

Dear Editor, I read with interest the recent discussion on the ENGAGE-AF trial written by
Kaba et al. 1 The authors provide a comprehensive discussion of the novel oral …

Abstract Background Direct oral anticoagulants (DOACs) are known to prevent thrombosis
but there is limited information about their activity on the clot formation and lysis cascade …

Both platelets and coagulation play key roles in initiation, amplification, and perpetuation of
acute coronary syndromes (ACS). Nonetheless, patients with ACS frequently have recurrent …

We acknowledge that the main shortcoming of our work was the limited number of
comparisons between the methods (STG-Drugscreen and calibrated automated …

Edoxaban, alongside other direct oral anticoagulants (DOAC), is increasingly used for
prevention of thromboembolism, including stroke. Despite DOAC therapy, however, annual …